Locomotor stimulant effects of nornicotine: Role of dopamine

Pharmacology Biochemistry and Behavior

Volumn 74, Issue 1, 2002, Pages 87-94

  Green, T A ^a   Brown, R W ^a   Phillips, S B ^a   Dwoskin, L P ^b   Bardo, M T ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b University of Kentucky   (United States)

Author keywords

Activity; Behavior; DOPAC; Locomotion; Metabolism; Nicotine metabolite; Sensitization; Synthesis; Tobacco alkaloid; Tolerance

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ETICLOPRIDE; NORNICOTINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE RECEPTOR BLOCKING; DRUG EFFECT; LOCOMOTION; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SENSITIZATION; TOBACCO DEPENDENCE;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; 3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; DIHYDROXYPHENYLALANINE; DOPAMINE; DOPAMINE ANTAGONISTS; DRUG SYNERGISM; MALE; MOTOR ACTIVITY; NICOTINE; NUCLEUS ACCUMBENS; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; SALICYLAMIDES; STIMULATION, CHEMICAL; SYMPATHECTOMY, CHEMICAL; SYMPATHOLYTICS;

NICOTIANA TABACUM;

EID: 0036887558     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(02)00960-7     Document Type: Article

References (36)

1. Balfour D.J., Benwell M.E. The role of brain dopamine systems in the psychopharmacological responses to nicotine. Asia Pac. J. Pharmacol. 8:1993;153-167.
2. Bardo M.T., Green T.A., Crooks P.A., Dwoskin L.P. Nornicotine is self-administered intravenously by rats. Psychopharmacology (Berlin). 146:1999;290-296.
3. Brazell M.P., Mitchell S.N., Joseph M.H., Gray J.A. Acute administration of nicotine increases the in vivo extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid and ascorbic acid preferentially in the nucleus accumbens of the rat: comparison with caudate-putamen. Neuropharmacology. 29:1990;1177-1185.
4. Clarke P.B., Pert A. Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res. 348:1985;355-358.
5. Clarke P.B., Fu D.S., Jakubovic A., Fibiger H.C. Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J. Pharmacol. Exp. Ther. 246:1988;701-708.
6. Copeland J.R., Adem A., Jacob P., Nordberg A. A comparison of the binding of nicotine and nornicotine stereoisomers to nicotinic binding sites in rat brain cortex. Naunyn-Schmiedeberg's Arch. Pharmacol. 343:1991;123-127.
7. Corrigall W.A., Coen K.M. Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology (Berlin). 104:1991;171-176.
8. Corrigall W.A., Franklin K.B., Coen K.M., Clarke P.B. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berlin). 107:1992;285-289.
9. Crooks P.A., Dwoskin L.P. Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochem. Pharmacol. 54:1997;743-753.
10. Crooks P.A., Li M., Dwoskin L.P. Determination of nicotine metabolites in rat brain after peripheral radiolabeled nicotine administration: detection of nornicotine. Drug Metab. Dispos. 23:1995;1175-1177.
11. Crooks P.A., Li M., Dwoskin L.P. Metabolites of nicotine in rat brain after peripheral nicotine administration. Cotinine, nornicotine, and norcotinine. Drug Metab. Dispos. 25:1997;47-54.
12. Damaj M.I., Martin B.R. Is the dopaminergic system involved in the central effects of nicotine in mice? Psychopharmacology (Berlin). 111:1993;106-108.
13. Dwoskin L.P., Buxton S.T., Jewell A.L., Crooks P.A. S(-)-Nornicotine increases dopamine release in a calcium-dependent manner from superfused rat striatal slices. J. Neurochem. 60:1993;2167-2174.
14. 3H]dopamine from superfused rat striatal slices. Eur. J. Pharmacol. 276:1995;195-199.
15. Dwoskin L.P., Crooks P.A., Teng L., Green T.A., Bardo M.T. Acute and chronic effects of nornicotine on locomotor activity in rats: altered response to nicotine. Psychopharmacology (Berlin). 145:1999;442-451.
16. (14)C]nicotine. Drug Metab. Dispos. 27:1999;1448-1455.
17. (14)C]nicotine. Drug Metab. Dispos. 29:2001;645-651.
18. Goldberg S.R., Risner M.E., Stolerman I.P., Reavill C., Garcha H.S. Nicotine and some related compounds: effects on schedule-controlled behaviour and discriminative properties in rats. Psychopharmacology (Berlin). 97:1989;295-302.
19. 3H]dopamine overflow from rat nucleus accumbens slices. Biochem. Pharmacol. 62(12):2001;1597-1603.
20. Grenhoff J., Svensson T.H. Selective stimulation of limbic dopamine activity by nicotine. Acta Physiol. Scand. 133:1988;595-596.
21. Grenhoff J., Aston-Jones G., Svensson T.H. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol. Scand. 128:1986;351-358.
22. Hentall I.D., Gollapudi L. The interpeduncular nucleus regulates nicotine's effects on free-field activity. NeuroReport. 6(18):1995;2469-2472.
23. Imperato A., Mulas A., Di Chiara G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur. J. Pharmacol. 132:1986;337-338.
24. Kyerematen G.A., Morgan M.L., Chattopadhyay B., deBethizy J.D., Vesell E.S. Disposition of nicotine and eight metabolites in smokers and nonsmokers: identification in smokers of two metabolites that are longer lived than cotinine. Clin. Pharmacol. Ther. 48:1990;641-651.
25. Mitchell S.N., Brazell M.P., Joseph M.H., Alavijeh M.S., Gray J.A. Regionally specific effects of acute and chronic nicotine on rates of catecholamine and 5-hydroxytryptamine synthesis in rat brain. Eur. J. Pharmacol. 167:1989;311-322.
26. O'Neill M.F., Dourish C.T., Iversen S.D. Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats. Psychopharmacology (Berlin). 104:1991;343-350.
27. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 3rd ed. 1997;Academic Press, San Diego, CA.
28. Pierce R.C., Crawford C.A., Nonneman A.J, Mattingly B.A., Bardo M.T. Effect of forebrain dopamine depletion on novelty-induced place preference behavior in rats. Pharmacol. Biochem. Behav. 36:1990;321-325.
29. Pontieri F.E., Tanda G., Orzi F., Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature. 382:1996;255-257.
30. 3H](-)-nicotine to rat brain membranes and its inhibition by analogues of nicotine. Neuropharmacology. 27:1988;235-241.
31. Self D.W., Nestler E.J. Relapse to drug-seeking: neural and molecular mechanisms. Drug Alcohol Depend. 51:1998;49-60.
32. Stolerman I.P., Garcha H.S., Mirza N.R. Dissociations between the locomotor stimulant and depressant effects of nicotinic agonists in rats. Psychopharmacology (Berlin). 117:1995;430-437.
33. Takada K., Swedberg M.D., Goldberg S.R., Katz J.L. Discriminative stimulus effects of intravenous L-nicotine and nicotine analogs or metabolites in squirrel monkeys. Psychopharmacology (Berlin). 99:1989;208-212.
34. 3H]dopamine. J. Pharmacol. Exp. Ther. 283:1997;778-787.
35. Vezina P., Blanc G., Glowinski J., Tassin J.P. Nicotine and morphine differentially activate brain dopamine in prefrontocortical and subcortical terminal fields: effects of acute and repeated injections. J. Pharmacol. Exp. Ther. 261:1992;484-490.
36. 3H]nicotine binding by the enantiomers of nicotine, nornicotine and anatoxin - a in membranes and solubilized preparations of different brain regions of rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 348:1993;28-34.